Danaher Corporation (DHR) is Reiterated by Stifel to Buy, Raises Price Target to $ 110

Danaher Corporation (DHR) was Reiterated by Stifel to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 110 from a previous price target of $109 . Stifel advised their investors in a research report released on Apr 22, 2016.

Many Wall Street Analysts have commented on Danaher Corporation. Company shares were Reiterated by RBC Capital Mkts on Apr 22, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 96 from a previous price target of $87 .Company shares were Reiterated by Barclays on Apr 18, 2016 to “Overweight”, Firm has raised the Price Target to $ 104 from a previous price target of $99 .Danaher Corporation was Downgraded by Bernstein to ” Mkt Perform” on Apr 4, 2016.

On the company’s financial health, Danaher Corporation reported $1.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 21, 2016. Analyst had a consensus of $1.03. The company had revenue of $5387.20 million for the quarter, compared to analysts expectations of $5329.83 million. The company’s revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.93 EPS.

Danaher Corporation opened for trading at $95.56 and hit $97.46 on the upside on Wednesday, eventually ending the session at $95.99, with a gain of 1.13% or 1.07 points. The heightened volatility saw the trading volume jump to 37,39,843 shares. Company has a market cap of $65,960 M.

In a different news, on Feb 29, 2016, Daniel Raskas (SVP-Corporate Development) sold 4,656 shares at $89.00 per share price. According to the SEC, on Feb 29, 2016, Walter G Lohr (director) sold 8,000 shares at $89.06 per share price. On Feb 11, 2016, Donald J Ehrlich (director) sold 8,000 shares at $86.00 per share price, according to the Form-4 filing with the securities and exchange commission.

Danaher Corporation (Danaher) designs manufactures and markets professional medical industrial and commercial products and services. It operates in five segments: Test & Measurement; Environmental; Life Sciences & Diagnostics; Dental and Industrial Technologies. The Test & Measurement segment offers test measurement and monitoring products. The Environmental segment products and services help protect the global water supply facilitate environmental stewardship and enhance the safety of personal data. The Company’s diagnostics business offers analytical instruments reagents consumables software and services. The Dental segment provides products that are used to diagnose treat and prevent disease and ailments of the teeth gums and supporting bone. The Company’s Industrial Technologies solutions help protect the world’s food supply improve packaging design and quality verify pharmaceutical dosages and authenticity and power innovative machines.

Danaher Corporation

Leave a Reply

Danaher Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Danaher Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.